Kura Oncology
KURA
Market cap $558M

6.44 USD

-0.22

3.30%

At close Jun 13, 4:00 PM EDT

After hours

6.45

+0.01

0.16%

1 day

-3.30%

5 days

-6.12%

1 month

11.03%

3 months

-11.54%

6 months

-33.13%

Year to date

-25.81%

1 year

-70.14%

5 years

-61.89%

10 years

-17.86%

About: Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Employees: 192

Healthcare Biotechnology

Funds holding %

of 7,296 funds

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]

7% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 57

0% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 36

7% less call options, than puts

Call options by funds: $596K | Put options by funds: $640K

1% less funds holding

Funds holding: 185 [Q4 2024] → 183 (-2) [Q1 2025]

1.71% less ownership

Funds ownership: 101.34% [Q4 2024] → 99.63% (-1.71%) [Q1 2025]

23% less capital invested

Capital invested by funds: $686M [Q4 2024] → $531M (-$155M) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

71%

upside

Avg. target

$27

323%

upside

High target

$40

521%

upside

4 analyst ratings

4 positive

100%

0 neutral

0 negative

JMP Securities Reni Benjamin	335%upside $28	Market Outperform Reiterated	4 Jun 2025
Mizuho Mara Goldstein	366%upside $30	Outperform Maintained	19 May 2025
Barclays Peter Lawson	71%upside $11	Overweight Maintained	2 May 2025
HC Wainwright & Co. Joseph Pantginis	521%upside $40	Buy Reiterated	28 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about KURA published over the past 30 days

Neutral

Zacks Investment Research

2 days ago

Is the Options Market Predicting a Spike in Kura Oncology Stock?

Investors need to pay close attention to KURA stock based on the movements in the options market lately.

Neutral

GlobeNewsWire

2 days ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML –

Positive

Zacks Investment Research

1 week ago

KURA Stock Rises More Than 15% This Past Week: Here's Why

Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.

Neutral

GlobeNewsWire

1 week ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Neutral

GlobeNewsWire

1 week ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile in heavily pre-treated patients: limited myelosuppression; no clinically meaningful QTc prolongation; 3% of patients discontinued due to treatment-related adverse events – – Potential first approval of a once-daily, oral menin inhibitor for treatment of adult patients with relapsed or refractory NPM1-mutated AML with Priority Review and a PDUFA target action date of November 30, 2025 – – Kura Oncology to host virtual investor event today at 7:30pm ET / 4:30pm PT – SAN DIEGO and TOKYO, June 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) announced the presentation of positive pivotal results from the KOMET-001 Phase 2 registration-directed trial of ziftomenib, a once-daily, oral investigational menin inhibitor, in patients with relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML) in an oral session today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from May 30 - June 3, 2025.

Neutral

GlobeNewsWire

1 week ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – SAN DIEGO and TOKYO, June 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced the U.S. Food and Drug Administration (FDA) has accepted Kura's New Drug Application (NDA) seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation.

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$